Akums Drugs & Pharmaceuticals Ltd.
NSE: AKUMS
NSE
445.80
7.00 (1.60%)
Prev Close
438.8
Open Price
449.85
Volume
28,558
Today Low / High
440.95 / 450.5
52 WK Low / High
405 / 622.95
Range
424 - 468
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 445.8, with a change of 7 (1.59526%). The expected target range on the NSE is between 424 - 468. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
02 Feb
435.00
0.87%
01 Feb
436.15
2.05%
30 Jan
434.20
1.38%
29 Jan
429.95
0.97%
28 Jan
430.45
-0.03%
27 Jan
431.55
-0.44%
23 Jan
420.35
0.84%
22 Jan
421.90
-0.38%
21 Jan
422.00
-0.53%
20 Jan
438.00
-3.82%
19 Jan
435.10
0.51%
16 Jan
440.35
0.82%
14 Jan
443.50
0.06%
13 Jan
446.80
-0.76%
12 Jan
447.00
-0.56%
09 Jan
447.00
-0.08%
08 Jan
456.05
-2.01%
07 Jan
446.85
1.85%
06 Jan
450.00
-1.29%
Akums Drugs & Pharmaceuticals Ltd. Graph
Akums Drugs & Pharmaceuticals Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Akums Drugs & Pharmaceuticals Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 445.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 445.80 | 450.26 | 405.23 - 495.28 |
| 454.72 | 363.77 - 545.66 | ||
| 459.17 | 321.42 - 596.93 | ||
| Bearish Scenario | 445.80 | 441.34 | 397.21 - 485.48 |
| 436.88 | 349.51 - 524.26 | ||
| 432.43 | 302.70 - 562.15 |
Overview of Akums Drugs & Pharmaceuticals Ltd.
ISIN
INE09XN01023
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
217,480
Market Cap
68,199,311,736
Last Dividend
0
Official Website
IPO Date
2024-08-06
DCF Diff
449.24
DCF
-10
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,071.09 Cr | 2,465.74 Cr | 1,605.36 Cr | 0.3943 | 0.00 Cr | 47.21 Cr | 310.65 Cr | 338.18 Cr | 22.60 | 529.11 Cr | 0.0831 |
| 2024-03-31 | 4,019.68 Cr | 2,582.22 Cr | 1,437.46 Cr | 0.3576 | 0.00 Cr | 50.51 Cr | 359.90 Cr | -4.04 Cr | -0.28 | 130.61 Cr | -0.0010 |
| 2023-03-31 | 3,474.76 Cr | 2,307.47 Cr | 1,167.29 Cr | 0.3359 | 0.00 Cr | 52.12 Cr | 191.31 Cr | 94.86 Cr | 6.03 | 309.08 Cr | 0.0273 |
| 2022-03-31 | 3,646.83 Cr | 2,377.83 Cr | 1,269.00 Cr | 0.3480 | 0.00 Cr | 35.89 Cr | 322.21 Cr | -252.54 Cr | -16.04 | -82.18 Cr | -0.0692 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 101.19 Cr | 4,113.44 Cr | 1,049.83 Cr | 3,047.0140 Cr | 88.21 Cr | -12.98 Cr | 680.93 Cr | 1,563.65 Cr | 0.00 Cr | 13.68 Cr | 0.00 Cr | 893.7470 Cr |
| 2024-03-31 | 111.05 Cr | 3,516.37 Cr | 2,795.88 Cr | 709.4980 Cr | 565.23 Cr | 454.18 Cr | 630.43 Cr | 1,390.67 Cr | 0.00 Cr | 13.14 Cr | 0.00 Cr | 1,210.5520 Cr |
| 2023-03-31 | 51.61 Cr | 3,266.53 Cr | 2,543.15 Cr | 717.1890 Cr | 619.09 Cr | 567.49 Cr | 729.80 Cr | 1,212.31 Cr | 0.00 Cr | 15.19 Cr | 0.00 Cr | 1,265.5670 Cr |
| 2022-03-31 | 55.14 Cr | 3,069.05 Cr | 2,443.88 Cr | 621.9760 Cr | 394.98 Cr | 339.84 Cr | 722.45 Cr | 1,059.94 Cr | 0.00 Cr | 11.34 Cr | 0.00 Cr | 1,272.4180 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 465.1960 Cr | -547.8430 Cr | 72.7880 Cr | 192.8840 Cr | -9.8590 Cr | 101.1910 Cr | -272.3120 Cr | 345.2530 Cr | -477.9000 Cr | 0.0000 Cr | -50.5710 Cr |
| 2024-03-31 | 498.2590 Cr | -330.4150 Cr | -108.0210 Cr | 186.8510 Cr | 59.4420 Cr | 111.0500 Cr | -311.4080 Cr | -45.2780 Cr | -49.1910 Cr | 0.0000 Cr | 83.7290 Cr |
| 2023-03-31 | 176.6310 Cr | -304.7020 Cr | 124.5400 Cr | -152.1620 Cr | -3.5310 Cr | 51.6080 Cr | -328.7930 Cr | 150.2970 Cr | 177.9810 Cr | 0.0000 Cr | -7.3470 Cr |
| 2022-03-31 | 31.8540 Cr | -234.8220 Cr | 236.0400 Cr | -225.7280 Cr | 33.0720 Cr | 55.1390 Cr | -257.5820 Cr | -193.1970 Cr | 261.3230 Cr | 0.0000 Cr | -292.5890 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1,017.53 Cr | 592.56 Cr | 424.97 Cr | 0.4176 | 56.61 Cr | 40.78 Cr | 2.66 | 123.44 Cr | 0.0401 |
| 2025-06-30 | 1,024.03 Cr | 581.92 Cr | 442.12 Cr | 0.4317 | 92.05 Cr | 63.48 Cr | 4.15 | 150.83 Cr | 0.0620 |
| 2025-03-31 | 1,008.48 Cr | 671.39 Cr | 337.09 Cr | 0.3343 | 57.40 Cr | 147.62 Cr | 0.00 | 115.48 Cr | 0.1464 |
| 2024-12-31 | 1,010.41 Cr | 602.39 Cr | 408.02 Cr | 0.4038 | 76.85 Cr | 65.18 Cr | 4.26 | 140.71 Cr | 0.0645 |
| 2024-09-30 | 1,033.09 Cr | 595.95 Cr | 437.14 Cr | 0.4231 | 86.32 Cr | 65.21 Cr | 4.37 | 138.35 Cr | 0.0631 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 229.10 Cr | 1,448.72 Cr | 1,677.82 Cr | 746.23 Cr | 648.36 Cr | 3,293.49 Cr | 1,568.04 Cr | 5,159.29 Cr | 1,990.86 Cr |
| 2025-03-31 | 101.19 Cr | 480.76 Cr | 581.95 Cr | 778.05 Cr | 680.93 Cr | 2,274.61 Cr | 1,563.65 Cr | 4,113.44 Cr | 1,049.83 Cr |
| 2024-09-30 | 482.00 Cr | 342.29 Cr | 824.29 Cr | 949.31 Cr | 659.60 Cr | 2,623.60 Cr | 1,412.70 Cr | 4,270.40 Cr | 1,423.42 Cr |
| 2024-03-31 | 111.05 Cr | 176.77 Cr | 287.82 Cr | 833.81 Cr | 630.43 Cr | 1,940.88 Cr | 1,390.67 Cr | 3,516.37 Cr | 2,795.88 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,682.70 | ₹4,037,360,954,019.00 | ₹2,175,122.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,244.50 | ₹1,657,718,547,810.00 | ₹98,152.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,042.00 | ₹1,367,996,468,480.00 | ₹159,874.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,224.00 | ₹1,019,063,464,560.00 | ₹528,921.00 |
| Lupin Limited | LUPIN | ₹2,169.00 | ₹990,797,031,000.00 | ₹204,948.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹900.35 | ₹905,962,772,897.00 | ₹271,538.00 |
| Mankind Pharma Limited | MANKIND | ₹2,122.90 | ₹876,343,887,349.00 | ₹63,792.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,230.40 | ₹714,618,316,939.00 | ₹978,482.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,667.50 | ₹677,634,637,500.00 | ₹34,484.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,964.00 | ₹554,242,388,876.00 | ₹162,495.00 |
| Laurus Labs Limited | LAURUSLABS | ₹981.65 | ₹529,950,213,720.00 | ₹735,288.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,450.20 | ₹367,921,856,944.00 | ₹22,979.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,793.20 | ₹348,970,184,957.00 | ₹14,592.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,896.40 | ₹304,248,934,000.00 | ₹55,916.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,514.10 | ₹287,031,782,814.00 | ₹46,641.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,359.00 | ₹220,826,857,671.00 | ₹314,141.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,670.50 | ₹216,762,500,000.00 | ₹3,564.00 |
| Eris Lifesciences Limited | ERIS | ₹1,423.60 | ₹193,918,366,028.00 | ₹40,260.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,510.00 | ₹173,331,800,390.00 | ₹33,838.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹989.10 | ₹156,643,517,747.00 | ₹39,283.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹789.85 | ₹155,255,383,491.00 | ₹36,998.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹848.30 | ₹151,938,902,721.00 | ₹280,562.00 |
| Cohance Lifesciences Limited | COHANCE | ₹384.50 | ₹147,097,065,330.00 | ₹110,639.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,841.60 | ₹139,983,139,354.00 | ₹33,193.00 |
| Granules India Limited | GRANULES | ₹567.25 | ₹137,653,829,151.00 | ₹190,121.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹946.40 | ₹116,157,350,400.00 | ₹28,498.00 |
| Viyash Scientific Limited | VIYASH | ₹214.98 | ₹93,775,471,074.00 | ₹766,380.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,247.00 | ₹87,096,957,354.00 | ₹9,080.00 |
| Strides Pharma Science Limited | STAR | ₹852.40 | ₹78,568,023,257.00 | ₹112,827.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹785.50 | ₹71,203,449,437.00 | ₹51,323.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹445.80 | ₹68,252,897,456.00 | ₹28,558.00 |
| FDC Limited | FDC | ₹380.50 | ₹61,949,236,962.00 | ₹42,113.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹297.35 | ₹58,156,252,988.00 | ₹194,189.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹139.17 | ₹45,163,669,402.00 | ₹1,180,523.00 |
| Innova Captab Limited | INNOVACAP | ₹728.45 | ₹41,685,499,530.00 | ₹27,907.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹397.55 | ₹36,284,388,500.00 | ₹90,829.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹325.30 | ₹35,446,400,705.00 | ₹46,236.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹674.65 | ₹34,217,644,188.00 | ₹24,730.00 |
| Suven Life Sciences Limited | SUVEN | ₹142.85 | ₹32,494,660,900.00 | ₹92,987.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,963.50 | ₹32,474,355,953.00 | ₹9,519.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹302.00 | ₹30,285,316,812.00 | ₹34,224.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹396.05 | ₹27,884,197,288.00 | ₹19,688.00 |
Key Executives
President of Human Resource
Arvind Srivastava
Gender: male
Year Born:
Company Secretary & Compliance Officer
Dharamvir Malik
Gender: male
Year Born:
Co Founder, MD & Director
Sandeep Jain
Gender: male
Year Born: 1967
President of Operations & Whole Time Director
Sanjay Kumar Sinha
Gender: male
Year Born: 1958
President of Strategy, New Projects & Business Excellence
Sanjay Sharma
Gender: male
Year Born:
President of CQA Formulation
Shantanu R. Chobhe
Gender: male
Year Born:
Chief Financial Officer
Sumeet Sood
Gender: male
Year Born:
Director of Corporate Growth & Excellence
Arushi Jain
Gender: female
Year Born:
General Manager of Strategy
Sahil Maheshwari
Gender: Not Specified
Year Born:
Co-Founder, MD & Whole Time Director
Sanjeev Jain
Gender: male
Year Born: 1966
FAQs about Akums Drugs & Pharmaceuticals Ltd.
Who is the CEO of the company?
The CEO is Sanjeev Jain.
What is the current market price of the stock?
The current price is ₹445.45.
What is the 52-week price range?
The range is ₹405-622.95.
What is the market capitalization of the company?
The market capitalization is ₹6,819.93 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 21.54.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Akums Drugs & Pharmaceuticals Ltd. (ISIN: INE09XN01023) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹6,819.93 crores and an average daily volume of 217,480 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.